Mini-dose esketamine-dexmedetomidine combination to supplement analgesia for patients after scoliosis correction surgery: a double-blind randomised trial.

What Was Tested

This randomized controlled trial looks at Copper (Supplement).

Patients often experience severe pain after scoliosis correction surgery.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

Amongst secondary outcomes, subjective sleep quality was assessed with an NRS score (0=best sleep and 10=worst sleep) for the first five postoperative nights.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

The primary outcome was the incidence of moderate-to-severe pain within 72 h, defined as a numeric rating scale (NRS: 0=no pain and 10=worst pain) score ≥4 at any of seven time points.

What Was Measured

PubMed files the paper under topics including Ketamine, Dexmedetomidine, Analgesia, Postoperative Pain and Scoliosis.

The authors tagged it with the keywords S(+)-ketamine, esketamine, multimodal analgesia, postoperative analgesia, scoliosis surgery and spine.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (British journal of anaesthesia), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.